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Amyotrophic lateral sclerosis (ALS) is a progressive and lethal disease of motor neuron degeneration, leading to paralysis of
voluntary muscles and death by respiratory failure within five years of onset. Frontotemporal dementia (FTD) is characterised
by degeneration of frontal and temporal lobes, leading to changes in personality, behaviour, and language, culminating in death
within 5–10 years. Both of these diseases form a clinical, pathological, and genetic continuum of diseases, and this link has become
clearer recently with the discovery of a hexanucleotide repeat expansion in the C9orf72 gene that causes the FTD/ALS spectrum,
that is, c9FTD/ALS. Two basic mechanisms have been proposed as being potentially responsible for c9FTD/ALS: loss-of-function
of the protein encoded by this gene (associated with aberrant DNA methylation) and gain of function through the formation of
RNA foci or protein aggregates. These diseases currently lack any cure or effective treatment. Antisense oligonucleotides (ASOs)
are modified nucleic acids that are able to silence targeted mRNAs or perform splice modulation, and the fact that they have proved
efficient in repeat expansion diseases including myotonic dystrophy type 1 makes them ideal candidates for c9FTD/ALS therapy.
Here, we discuss potential mechanisms and challenges for developing oligonucleotide-based therapy for c9FTD/ALS.
1. Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive and lethal
disease characterised by degeneration of motor neurons,
leading to paralysis of voluntary muscles [1], culminating in
respiratory failure and death within five years of disease onset
[2, 3]. Frontotemporal dementia (FTD) is a cause of presenile
dementia, being the second most common form of dementia
in individuals younger than 65 years [4]. It is characterised by
degeneration of the frontal and temporal lobes of the brain
leading to changes in personality, behavior, and language,
though with some preservation of perception and memory
[2, 5]. FTD patients die 5–10 years after disease onset [6].
Both diseases are incurable. Recently, a hexanucleotide repeat
expansion in the C9orf72 gene has been described that is
responsible for what is called the c9FTD/ALS continuum.
This repeat expansion is now known to be the most common
cause for familial c9FTD/ALS, and it has also been observed
in apparently sporadic cases [7, 8]. The mechanism by which
the repeat expansion causes disease remains to be clarified
and both loss- and gain-of-function mechanisms have been
proposed. Using knowledge obtained through research into
antisense oligonucleotides (ASOs) therapies for diseases such
as Duchenne muscular dystrophy (DMD) and myotonic
dystrophy type 1, we propose that using such therapy may be
a promising approach for treating C9orf72 repeat expansion
in c9FTD/ALS.
2. Discovery of the C9orf72 Mutation That
Causes FTD/ALS
ALS and FTD share clinical, pathological, and genetic char-
acteristics, supporting the hypothesis that these two illnesses
form a spectrum of disease. Evidence for the existence of this
spectrum comes from many different studies. For example,
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it is now known that up to 50% of ALS patients have some
impairment of frontotemporal function and ∼15% of ALS
patients can specifically be said to have FTD [9–13]. In
addition, significant corticospinal and lower motor neuron
dysfunction have been observed across most FTD sub-
types, with 10–15% of FTD patients having coexisting motor
neuron disease (MND) [11, 14]. Another highly important
pathological link is the recognition that transactive response
DNA binding protein 43 kDa (TDP-43) aggregates can be a
common pathological hallmark in both ALS and FTD [15].
Prior to the discovery of the C9orf72 expansion, sev-
eral genes were already known to be responsible for the
development of ALS, such as superoxide dismutase 1 (SOD1)
[16]. However, among families where both ALS and FTD
cases are clustered together, strong linkage to chromosomal
locus 9p21 was identified and defined as causative for the
FTD/ALS spectrum [17, 18]. The associated risk haplotype
has since been shown to be the same in all ALS and FTD
populations studied, and is also present in affected members
of several FTD/ALS families, suggesting a single founder
mutation effect [19].
3. The Repeat Expansion in the C9orf72 Gene
Is Responsible for c9FTD/ALS
A study of an autosomal dominant kindred of FTD/ALS
found a hexanucleotide GGGGCC repeat expansion within
the C9orf72 gene in affected individuals [7]. In their FTD
patient series, the authors found that 3% of sporadic and
11.7% of familial patients carried the repeat expansion. In
their ALS subjects, 4.1% of sporadic and 23.5% of famil-
ial cases had the expansion. When compared with other
mutations responsible for ALS, this expansion mutation was
the most common genetic cause of sporadic and familial
ALS in their clinical series. In FTD, the expansion was also
found to be the main cause of familial cases and of equal
frequency to the progranulin (GRN) mutations in sporadic
FTD. Unrelated carriers of the expanded repeat all shared
at least one copy of the identified haplotype. The repeat
length in healthy individuals ranged from 2 to 23 units,
whereas the estimated size in FTD/ALS patients was 700–
1600 units [7]. The minimal expansion size for the disease
to occur remains undetermined, and it is important to note
that genetic anticipation, which means that the phenotype is
more severe at an earlier age as the disease is passed through
generations and the repeat expansion increases in size, was
not apparent in themajority of families studied [7]. In parallel
to this study, the same repeat expansion in the C9orf72 gene
was recognized as being responsible for 46% of familial ALS
and 21.1% of sporadic ALS in the Finnish population [8]. It
was also found to be present in one third of familial ALS
cases of outbred European origin. In addition, some 30% of
the Finnish FTD cohort were found to have the mutation,
making it the most common genetic cause of FTD/ALS. This
study again found no evidence of anticipation; however, the
data about the at-risk haplotype was slightly discordant with
the study of DeJesus-Hernandez et al., [7] since they found
the expansion also to be present in ALS cases without this
haplotype group [8]. Following on from the publication of
these original two reports, many further studies have since
confirmed the presence of the C9orf72 expansion in familial
FTD/ALS cases in various different populations from around
the world; for example, Gijselinck et al. also found the same
repeat expansion in a Flanders-Belgian cohort study [20].
4. Phenotype and Pathology of c9FTD/ALS
The clinical phenotype for repeat expansion carriers includes
older age of onset, shorter disease duration, psychotic symp-
toms, bulbar onset of ALS, and a predominantly behavioural
variant of FTD [21–25]. The pathology of C9orf72-related
disease includes TDP-43 positive inclusions and also some
inclusions that are TDP-43 negative but p62/ubiquitin pos-
itive in specific parts of the brain, such as cerebellum and
hippocampus [22, 25–28]. TDP-43 is a protein that is able to
bindRNA,DNA, and other proteins and ismainly involved in
transcription and splicing regulation [29]. Such inclusions are
also found in some patients with different genetic mutations;
however, classic mutations like those in SOD1 and fused in
sarcoma (FUS), which itself has some similarity in function to
TDP-43 such as involvement in DNA repair and in regulation
of transcription and RNA splicing [30], are not associated
with TDP-43 pathology. The differences between C9orf72-
associated disease and the other main genes involved in FTD
and/or ALS are summarised in Table 1.
With the discovery of C9orf72-related hexanucleotide
expansions, much (though not all) of the previously unex-
plained heritability of familial ALS has been clarified. Prior
to this, mutations in the SOD1 gene were the most commonly
identified cause; however, these explained at best some 20%of
familial ALS cases, with mutations in other genes accounting
for considerably less. In contrast, C9orf72 expansions have
now overtaken SOD1 as the single leading identifiable cause
of familial ALS [6, 31].
5. Potential Mechanisms of c9FTD/ALS
The C9orf72 gene produces three transcripts initiated from
two alternative transcription start sites. Two of the transcripts
comprise 11 exons but use alternative first exons, 1a or 1b.
The other transcript is truncated with just 5 exons and uses
a truncated version of exon 1a. Unfortunately, the naming of
these transcripts has been somewhat inconsistent within the
literature and among internet databases, leading to potential
confusion. In this review, we therefore choose to use a clearer
naming system, whereby the two longer transcripts with 11
exons are called variant 1a and variant 1b (NM 001256054 and
NM 018325, resp.), while the shorter transcript is variant Δ1a
(NM 145005). These three transcripts lead to the expression
of just two protein isoforms. Variants 1a and 1b encode a
protein of 481 amino acids, while variant Δ1a encodes a
shorter 222 amino acid protein (Figure 1). These transcripts
have been found in a variety of tissues and have been shown
to localise to the cytoplasm of neurons [7]. Recently, the
product of this gene was identified as being a homologue of
DENN domain proteins (differentially expressed in normal
and neoplastic cells), which are GDP/GTP exchange factors
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Table 1: Comparison of pathology, clinical features, and prevalence of distinct FTD and/or ALS causative genes.
Pathology Clinical feature Prevalence References
TDP-43 P62/ubiquitin Ubiquilin2 FUS SOD1 Tau
FTD/ALS C9orf72 + + −
−
−
−
ALS—weakness in
limbs (50–70%),
bulbar involvement,
dementia, and
psychosis.
FTD—behavioural
variant, psychiatric
symptoms.
60% hereditary
ALS-FTD
Up to 21% sporadic
ALS
7–10% sporadic
FTD
[22, 25–28]
FTD/ALS UBQLN2 + + + + − −
ALS—upper motor
neuron with
spasticity, bulbar and
pseudobulbar
dysfunction, lower
motor neuron
involvement not
prominent, and
dementia.
FTD—behavioural
variant.
5 families [32, 33]
ALS FUS − + − + − −
Lower motor neuron
signs with limbs and
bulbar distribution,
and upper motor
neuron signs are
common.
4-5% familial ALS
0.5–0.7% sporadic
ALS
[24, 29, 30,
34, 35]
ALS SOD1 − + −
−
+
−
Lower and upper
motor neuron signs,
bulbar onset is
unusual, and
weakness in limbs is
asymmetric.
12-13% familial
ALS
1–3% sporadic ALS
[24, 36, 37]
ALS TARDBP + + −
−
−
−
Weakness in arms
before legs, few
patients with bulbar
involvement, and
upper motor neuron
involvement with
mild or absent
spasticity.
3–6% familial ALS
8 patients
described sporadic
ALS
[24, 38]
FTD tau (MAPT) − − −
−
− +
Behavioural variant,
progressive nonfluent
aphasia.
Up to 50% of total
FTD patients [39–41]
FTD FUS − + − + − − Behavioural variant. <1% of total FTDpatients [28, 41]
FTD-TDP(GRN) + + −
−
−
−
Behavioural variant,
semantic dementia,
and progressive
nonfluent aphasia.
3–26% of total
FTD patients
[15, 36, 41–
44]
(GEF) that activate Rab-GTPases and that are involved in
membrane trafficking [45].
6. Loss-of-Function Mechanism
The GGGGCC hexanucleotide repeat is located between the
two alternative noncoding first exons 1a and 1b. It therefore
lieswithin the promoter region of variant 1b andwithin intron
1 of variants 1a and Δ1a. In patients studied by DeJesus-
Hernandez et al. [7], there was an absence of variant 1b
(variant 1 in the original paper) transcribed from the mutant
allele, leading to a ∼50% reduction in this variant but normal
transcription of variants Δ1a and 1a (variants 2 and 3). This
finding potentially implicates a loss of gene function as
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Figure 1: Structure of the C9orf72 locus and its three primary transcripts. Two alternative first exons are used, 1a and 1b, and both of these lie
upstream of the translation start site. Between exons 1a and 1b lies the hexanucleotide expansion region. Note that two putative CpG islands
lie either side of the expansion.The shorter of these regions, CpG 20, overlaps with much of the sequence of exon 1a. Although there are three
transcripts, the position of the ATG start codon in exon 2 means that only two protein isoforms are translated: isoform A is 481 amino acids
long, while the shorter isoform B is only 222 amino acids in length.
the cause of the disease [2]. Important supporting evidence
for this mechanism was found recently by Ciura et al. [46].
They found that morpholino-induced knockdown of the
zebrafish homologue of the C9orf72 gene caused axonal
degeneration in motor neurons, leading to behavioural and
cellular deficits that affected locomotion without morpho-
logical abnormalities. Most importantly, this phenotype was
rescued upon overexpression of humanC9orf72mRNA tran-
scripts. Another important finding that may point towards
haploinsufficiency is that large hexanucleotide expansions
have been shown to be associated with increased CpGmethy-
lation of the C9orf72 promoter, which would be expected to
lead to downregulation of gene expression [47].
7. Gain-of-Toxic-Function Mechanism
Aside from haploinsufficient loss-of-function theories of
pathogenesis, several gain-of-function hypotheses have been
suggested. One such mechanism may occur through the
formation of RNA foci, which are known to play an important
role in the pathogenesis of several other noncoding repeat
expansion disorders, like myotonic dystrophy type 1 [48]. In
these disorders, RNA foci have been shown to sequester RNA-
binding proteins, which lead to dysregulation of alternative
mRNA splicing [2, 49–52]. The observation that such RNA
foci are indeed present in the nuclei of frontal cortex neurons
and spinal cord lower motor neurons of c9FTD/ALS patients
potentially supports this gain of toxic function mechanism
[7].
Another gain-of-functionmechanism has been proposed
whereby the intronic repeat expansion is translated into
dipeptide-repeat proteins through a mechanism of transla-
tion not requiring ATG initiation. The translation of the
GGGGCC repeat in its three possible reading frames would
form poly-(Gly-Ala), poly-(Gly-Pro), and poly-(Gly-Arg).
Such dipeptide proteins would be extremely hydrophobic,
tending to form intracellular aggregates, and such inclusions
have indeed been reported in brain homogenates from
c9FTD/ALS patients [53, 54].
8. Current Available Therapies for ALS
Riluzole is an inhibitor of glutamate release that acts as
a neuroprotective therapy for patients with ALS, and it is
currently the only Food and Drug Administration (FDA)
approved drug with any proven efficacy to treat this disease.
However, the beneficial effects are very modest [55]. Apart
from riluzole administration, the management of patients is
mostly in terms of symptomatic treatment. Alternative and
offlabel treatments are also available and include insulin-like
growth factor-1, lithium carbonate [56], minocycline [57],
and stem cell therapy [58]. Lithium treatment slowed down
progression of the disease in human patients, and in a mouse
model, it showed decreased cell death in certain regions
and was found to affect multiple targets that may together
contribute to the improvement observed [56]. Minocycline
has antiapoptotic and anti-inflammatory effects in vitro and
went to a phase III clinical trial (http://clinicaltrials.gov/
identifier: NCT00047723) but was found to have harmful
effects in ALS patients [57]. Antioxidants were also thought
to have neuroprotective effects; however, several of them
showed no significant effect in clinical trial for this disease
[59].
9. Current Available Therapies for FTD
FTD does not have any FDA approved drugs; however, some
offlabel psychiatric drugs are used including antidepressants
and some drugs used for Alzheimer’s disease [60–62]. For
additional indication for FTD, there is an ongoing phase IV
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clinical trial testing the drug memantine (NCT00545974),
which is already approved for use in Alzheimer’s disease
[60, 61].
10. Development of Oligonucleotide-Based
Therapy
Antisense oligonucleotides are short, synthetic, andmodified
nucleic acids that are able to bind to mRNA or pre-mRNA
via base-pairing and to interfere in its function by silencing
or through some other form of modulation [63]. ASOs are
able to perform their function either by binding to the RNA
without inducing RNA degradation or through promoting
the degradation of the target RNA via enzymes such as RNase
H [64, 65]. RNase H can recognize almost any RNA-DNA
heteroduplex, and after this first step, it cleaves the RNA and
sets the DNA free. This means that ASOs that can mimic
this heteroduplex structure when they bind RNA are also
able to recruit RNase H, resulting in cleavage of their target
RNA while the ASO is preserved intact. This allows a single
ASO to interact with multiple RNAs, enhancing the overall
silencing effect [63, 66]. ASOs that act by this mechanism can
achieve 80–95% downregulation of protein and mRNA [67].
Other ASOs can also modulate RNA without degradation,
for example, through the use of splice modulation to affect
the gene product, as is observed for the exon-skipping based
therapy currently in development for DMD [68–71].
To perform their function in an effective manner, ASOs
have to reach themRNAor pre-mRNA in the relevant cellular
compartment (e.g., the nucleus) and to successfully hybridize
with their target. This requires a molecule with a sufficient
half-life and one that is also efficiently taken up by cells. Since
unmodified nucleic acids are rapidly degraded by endonu-
cleases and since this may lead to unexpected toxicity or
increase in off-target effects if high doses are required, several
chemicalmodifications have been developed to achieve better
functioning ASOs [63] (Figure 2).
11. Potential ASO Drugs
Modifications to the phosphate backbone of nucleic acids
can give rise to structures more resistant to degradation by
nucleases, and this increases the ASO half-life. Particularly
important members within this class of modification are the
phosphorodiamidate morpholino oligomers (PMOs), which
have high resistance to nucleases and are not substrates for
RNase H cleavage. PMOs are used for nondegradative pur-
poses such as splice modulation or translational interference
[63]. Morpholino antisense oligonucleotides also have some
advantages over other types of ASO; they have a higher
specificity, and it is suggested that they have fewer off-target
effects [72]. PMOs have been successfully used in preclinical
research and in clinical trials aimed at exon-skipping in
DMD, and currently, a phase IIb exon-skipping clinical trial
is ongoing with PMO [68–71] (NCT01396239) (Figure 3).
Another class of modifications is those made to the sugar
ring, which can increase both the RNA-binding affinity and
nuclease resistance, leading to enhanced metabolic stability
and better pharmacokinetic and toxicological properties
[64, 73]. However, such modifications generally lead to
loss of RNase H cleavage, and so “gapmer” structures were
developed where sugar-modified residues are present either
side of a modified backbone ASO. The external sugar-
modified residues thus enhance RNA binding, while the
internal backbone-modified residues still allow RNase H
cleavage [63]. The locked nucleic acid (LNA) is one of the
oligonucleotides that has such modifications, and it has great
thermal stability, is resistant to exonucleolytic degradation,
has good aqueous solubility, and is easy to synthesize [74].
The conformational change observed in the LNA structure
mimics RNA and increases target specificity, making this
a great therapeutic candidate [75, 76]. In 2005, an LNA-
antisense drug to treat chronic lymphocytic leukemia entered
phase I/II clinical trials (NCT00285103). Another sugar
modification is the 2󸀠OMe modification, which improves
thermal stability of the oligonucleotide/RNA hybrid. This
alteration, when associated with backbonemodifications, can
also lead to resistance to endonuclease degradation [73]. The
2󸀠OMe with phosphorothioate modification (2󸀠OMePS) can
improve the stability of ASO. Currently, there are clinical
trials for exon skipping in DMD using a 2󸀠OMe backbone
modified oligonucleotide, including one phase III trial [71,
77] (NCT01254019) (Figure 3).
12. Therapeutic Benefits of Using ASO Drugs
One further attractive benefit to using ASOs as therapy is that
they do not need viral or lipid carriers in contrast to other
types of RNA-targeting therapy. This reduces the likelihood
of an immune response [63]. Most of the ASO applications
in development are likely to be achievable through systemic
delivery. However, for neurological diseases, there is evidence
that direct delivery to the central nervous system may be
a better option. In order to reach the brain, systemically
delivered ASOs have to cross the blood-brain barrier (BBB).
Passage across the BBB is extremely hard for large molecular
weight compounds such as ASOs, and to date, no reliably
consistent method has been developed that can achieve
this. Using currently available ASO chemistries, it is likely
that any hope of significant BBB penetration would at the
very least require massively increased systemic dosing to a
degree that would likely result in toxicity [63, 78, 79]. It
has, however, been shown that therapeutic doses of ASOs
can be delivered intrathecally in nonhuman primates [80,
81]. This approach, although more invasive than systemic
delivery, is routinely used for common clinical indications
such as steroid, analgesia, or anaesthesia delivery [82–84]
and suggests that this route may be a clinically feasible
option. Delivery into the cerebral ventricles is also a possible
option, since they contain the cerebrospinal fluid (CSF) that
circulates around the brain and spinal cord approximately 3
times a day [81, 85]. Although this approach is invasive and
generally requires neurosurgical placement of an indwelling
cerebroventricular catheter, it is a route that is on occasion
required for clinical drug delivery [86, 87].
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Figure 2: Chemical structures of commonly used oligonucleotides. Nucleic acids can bind to RNA targets that are complementary to their
own sequence and trigger target degradation. However, unmodified DNAs/RNAs are subject to endonuclease degradation. Thus, to target
RNAs, modifications to this primary structure are needed. Modifications to the nucleic acid backbone can lead to structures that can better
interact with the target and are resistant to endonucleases. Modifications in the sugar ring are also possible and give rise to nucleic acids that
mimic RNA, have better targeting, and are also resistant to endonuclease action.
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Figure 3: Strategy for exon 51-skipping in Duchenne muscular dystrophy. Exon 51-skipping by appropriate PMO or 2󸀠OMePS, indicated by
a blue line, can restore the reading frame of dystrophin in a DMD patient, who lacks exon 52 in the mRNA of the DMD gene, leading to
out-of-frame products. Dot line and Ex indicate introns and exons, respectively.
13. A Perspective on Oligonucleotide-Based
Therapy for c9FTD/ALS
ASO therapies can treat gain-of-function disorders by silenc-
ing the causative gene, either acting on both alleles for non-
essential genes or by selectively acting on the mutant allele
in the case of essential genes. For certain loss-of-function
diseases, there is also the possibility of using ASOs for splice
modulation, which can in certain cases restore the gene
function or otherwise compensate for its loss [63]. Since
c9FTD/ALS is a disease for which both of these pathogenic
mechanisms have been proposed, the use of oligonucleotides
for therapy is an attractive option.
In conjunction with this, it is notable that there are
several neurodegenerative diseases for which research into
ASO therapy is already being performed, including the form
of ALS caused by mutations in the SOD1 gene [81, 88]
(NCT01041222). The TDP-43 mutations in familial and spo-
radic ALS are also a target of knocking down therapies, and
recently, the inhibition of a RNA lariat debranching enzyme
led to reduced TDP-43 toxicity in yeast and neuronal models
[89]. These facts are important because such researches are
helping to set the parameters for ASO therapy in ALS and
within the central nervous system.
14. Therapeutic Potential of
Oligonucleotide-Based Therapy for Other
Neurodegenerative Diseases
Most importantly, some of the neurodegenerative diseases
under investigation are caused by trinucleotide repeat expan-
sions, and evidence of successful ASO therapeutic strategies
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Figure 4: Strategy for ASO-based knocking down of the C9orf72 gene in a c9FTD/ALS patient. Using antisense oligonucleotides (ASO)
targeting the GGGGCC repeat expansion can lead to selective knocking down of themutant allele which could otherwise cause the formation
of RNA foci. It also preserves the expression of the normal allele that may have an important function for cell survival. ASO is indicated by a
blue line, dot line indicates introns, and squares indicate exons.
for this type of disorder is rapidly accumulating. A remark-
able example is Huntington’s disease, in which an inherited
CAG expansion in the HTT gene causes progressive chorea,
psychiatric disturbance, and generalised cognitive deterio-
ration [63]. Unaffected individuals have up to 35 repeats in
the HTT gene, while affected patients have from 36 to more
than 100 repeats [90]. Trinucleotide repeats are able to form
hairpin structures [91], and the different number of repeats
in wild type and mutated alleles makes it possible to conduct
selective inhibition, since each allele will have a different
hairpin structure [92]. In this case, selective silencing is
needed, since the HTT is an essential gene [93, 94]. In a
study performed by Hu et al. [92], selective inhibition of
the HTT mutant allele with a certain number of repeats
was achieved without affecting other genes containing CAG
repeats. In the same study, the authors showed that the
same approach can also be used for spinocerebellar ataxia
type 3, which is another CAG repeat expansion disorder
in which the protein affected is ataxin-3 that is involved in
deubiquitination and proteasomal protein degradation [95].
These findings show that selective inhibition is feasible for
other CAG repeat expansion disorders. Infusion of ASOs into
the central nervous system provided long-term reduction
in the mutated huntingtin protein, and it was shown that
a certain degree of wild type protein suppression can be
tolerated [80]. Additional studies have been done to show
that repeat expansion disorders like Huntington’s disease and
spinocerebellar ataxia type 3 can be successfully treated with
ASOs [96]. For spinocerebellar ataxia type 3 exon skipping
can be performed, since the protein disrupted in this case
is essential, and so restoration of its expression is desirable
[97]. Another repeat expansion disease that has been shown
to be treatable by ASO therapy is myotonic dystrophy type
1, which has a CTG repeat expansion. This disease, most
significantly, has the repeat expansion in a noncoding region
[98, 99] and is known to form RNA foci [100, 101], making it
similar to c9FTD/ALS. Applying ASOs that utilize the RNase
Hmechanism in a transgenicmousemodel, gene knockdown
and amelioration of pathology were observed [102].
The existence of successful studies that were able to
ameliorate the effects of repeat expansion diseases shows
the feasibility of ASO therapy in such diseases, raising the
possibility of developing anASO therapy for c9FTD/ALS.The
possibility of selective suppression of mutant alleles is also a
point that has to be considered, since the exact function of
the C9orf72 protein has yet to be studied and since selective
inhibition may be important. Our preliminary data suggest
that oligonucleotide-based therapy targeting C9orf72 may
be effective in patient-derived fibroblast cells (Figure 4).
In addition, the knowledge and expertise obtained from
preclinical and clinical studies for the ASO-based treatment
of DMD, sporadic ALS, and myotonic dystrophy type 1 could
be applicable to c9FTD/ALS in order to develop promising
oligonucleotide-based drugs.
15. Conclusion
The recent discovery of the hexanucleotide repeat expansion
in theC9orf72 gene as the causative agent of c9FTD/ALS gives
rise to the opportunity to develop new therapies directed at
this mutation, which is responsible for a large proportion
of FTD and/or ALS cases. ASOs are now becoming more
widespread in use as gene therapies, and the possibility of
chemical modifications that can enhance their properties
makes them great candidates for drug development. The
recent advances in the development ofASOs therapies for dis-
eases of the central nervous system and in repeat expansion
8 Journal of Nucleic Acids
diseases highlight the potential of this approach for targeting
the newly discovered c9FTD/ALS mutation.
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